174 related articles for article (PubMed ID: 34488779)
1. Biologic medicine inclusion in 138 national essential medicines lists.
Kraus R; Yeung RSM; Persaud N
Pediatr Rheumatol Online J; 2021 Sep; 19(1):140. PubMed ID: 34488779
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
3. Relation between opioid consumption and inclusion of opioids in 137 national essential medicines lists.
Richards GC; Aronson JK; Heneghan C; Mahtani KR; Koshiaris C; Persaud N
BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33173012
[TBL] [Abstract][Full Text] [Related]
4. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
[TBL] [Abstract][Full Text] [Related]
5. Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists.
Jarvis JD; Woods H; Bali A; Oronsaye E; Persaud N
PLoS One; 2019; 14(8):e0220781. PubMed ID: 31398195
[TBL] [Abstract][Full Text] [Related]
6. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
Donges E; Staatz CE; Benham H; Kubler P; Hollingworth SA
Clin Exp Rheumatol; 2017; 35(6):907-912. PubMed ID: 28421991
[TBL] [Abstract][Full Text] [Related]
7. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
8. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
10. Insights from the WHO and National Lists of Essential Medicines: Focus on Pediatric Diabetes Care in Africa.
Rowlands A; Ameyaw E; Rutagarama F; Dipesalema J; Majaliwa ES; Mbogo J; Ogle GD; Chanoine JP
Horm Res Paediatr; 2018; 90(2):82-92. PubMed ID: 30048982
[TBL] [Abstract][Full Text] [Related]
11. Comparison of essential medicines lists in 137 countries.
Persaud N; Jiang M; Shaikh R; Bali A; Oronsaye E; Woods H; Drozdzal G; Rajakulasingam Y; Maraj D; Wadhawan S; Umali N; Wang R; McCall M; Aronson JK; Plüddemann A; Moja L; Magrini N; Heneghan C
Bull World Health Organ; 2019 Jun; 97(6):394-404C. PubMed ID: 31210677
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
13. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
Graudal N; Hubeck-Graudal T; Tarp S; Christensen R; Jürgens G
PLoS One; 2014; 9(9):e106408. PubMed ID: 25244021
[TBL] [Abstract][Full Text] [Related]
15. OS032. Pharmacotherapy for pre-eclampsia in low and middle income countries: An analysis of essential medicines lists (EMLS).
Lalani S; Firoz T; Magee LA; Lowe R; Sawchuck D; Payne B; Gordon R; Vidler M; von Dadelszen P
Pregnancy Hypertens; 2012 Jul; 2(3):193-4. PubMed ID: 26105246
[TBL] [Abstract][Full Text] [Related]
16. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
17. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey.
Gaitonde P; Bozzi LM; Shaya FT
Semin Arthritis Rheum; 2018 Apr; 47(5):649-653. PubMed ID: 29153870
[TBL] [Abstract][Full Text] [Related]
19. Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
Calip GS; Patel PR; Sweiss K; Wu Z; Zhou J; Asfaw AA; Adimadhyam S; Lee TA; Chiu BC
Int J Cancer; 2020 Sep; 147(5):1300-1305. PubMed ID: 31997371
[TBL] [Abstract][Full Text] [Related]
20. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Levesque MC
BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
